Mylan Recalls 15 Batches of Valsartan Globally, for the Treatment of Hypertension

 Mylan Recalls 15 Batches of Valsartan Globally, for the Treatment of Hypertension

Mylan Recalls 15 Batches of Valsartan Globally, for the Treatment of Hypertension

Shots:

  • Mylan has recalled globally, 6 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, and 10mg/320mg strengths), 7 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg, and 320 mg strengths) and 2 lots of Valsartan and Hydrochlorothiazide Tablets, USP (320mg/25mg strength) , detected with traces of N-nitrosodiethylamine (NDEA)
  • The voluntarly recall is done for the lots of Valsartan, distributed between Mar, 2017 and Nov, 2018. European Union authorities has already ban sales of valsartan few days’ back
  • Valsartan is a combination of amlodipine or hydrochlorothiazide indicated for the treatment of high blood pressure, heart failure and in reduction of cardiovascular mortality

Click here to read full press release/ article | Ref: Mylan | Image: Daily Post India

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post